PPARG and type 2 diabetes mellitus: This led to the hypothesis thatinsulin sensitivity may itself play an important role in the development ofmacrovascular disease, and that agents that reduce insulin resistance, such asmetformin and PPARγ agonists,by extension, may have particular benefits in the management of type 2 diabetes[55].